| Dr David J Bearss, MD | |
|
1035 Lincolnton Rd, Salisbury, NC 28144-6277 | |
| (704) 637-1123 | |
| (704) 637-1214 |
| Full Name | Dr David J Bearss |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 1035 Lincolnton Rd, Salisbury, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063408235 | NPI | - | NPPES |
| 8914149 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 9600858 (North Carolina) | Secondary |
| 208000000X | Pediatrics | 9600858 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advanced Home Care | Salisbury, NC | Home health agency |
| Gentiva Health Services | Kernersville, NC | Home health agency |
| Bayada Home Health Care, Inc | Salisbury, NC | Home health agency |
| Novant Health Rowan Medical Center | Salisbury, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novant Medical Group Inc | 1153234893 | 1996 |
News Archive
Valeant Pharmaceuticals International, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for efinaconazole for the treatment of onychomycosis.
The California Mental Health Services Authority (CalMHSA), a newly formed California joint powers authority (JPA) of counties focused on the efficient delivery of California mental health projects and programs, announced today it has entered into a contract with the California Department of Mental Health (CDMH) to provide program development, administrative oversight, and fiscal management services to county members and other program participants choosing to assign specifically named mental health funds to the joint powers authority.
Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.
Probiotic supplements protected female mice from the loss of bone density that occurs after having their ovaries removed, researchers at Emory University School of Medicine and Georgia State University have shown.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
› Verified 4 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366409492 PECOS PAC ID: 1153234893 Enrollment ID: O20031121000692 |
News Archive
Valeant Pharmaceuticals International, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for efinaconazole for the treatment of onychomycosis.
The California Mental Health Services Authority (CalMHSA), a newly formed California joint powers authority (JPA) of counties focused on the efficient delivery of California mental health projects and programs, announced today it has entered into a contract with the California Department of Mental Health (CDMH) to provide program development, administrative oversight, and fiscal management services to county members and other program participants choosing to assign specifically named mental health funds to the joint powers authority.
Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.
Probiotic supplements protected female mice from the loss of bone density that occurs after having their ovaries removed, researchers at Emory University School of Medicine and Georgia State University have shown.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
› Verified 4 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306950282 PECOS PAC ID: 1153234893 Enrollment ID: O20040204001028 |
News Archive
Valeant Pharmaceuticals International, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for efinaconazole for the treatment of onychomycosis.
The California Mental Health Services Authority (CalMHSA), a newly formed California joint powers authority (JPA) of counties focused on the efficient delivery of California mental health projects and programs, announced today it has entered into a contract with the California Department of Mental Health (CDMH) to provide program development, administrative oversight, and fiscal management services to county members and other program participants choosing to assign specifically named mental health funds to the joint powers authority.
Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.
Probiotic supplements protected female mice from the loss of bone density that occurs after having their ovaries removed, researchers at Emory University School of Medicine and Georgia State University have shown.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David J Bearss, MD Po Box 60447, Charlotte, NC 28260-0447 Ph: (704) 637-1123 | Dr David J Bearss, MD 1035 Lincolnton Rd, Salisbury, NC 28144-6277 Ph: (704) 637-1123 |
News Archive
Valeant Pharmaceuticals International, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for efinaconazole for the treatment of onychomycosis.
The California Mental Health Services Authority (CalMHSA), a newly formed California joint powers authority (JPA) of counties focused on the efficient delivery of California mental health projects and programs, announced today it has entered into a contract with the California Department of Mental Health (CDMH) to provide program development, administrative oversight, and fiscal management services to county members and other program participants choosing to assign specifically named mental health funds to the joint powers authority.
Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.
Probiotic supplements protected female mice from the loss of bone density that occurs after having their ovaries removed, researchers at Emory University School of Medicine and Georgia State University have shown.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
› Verified 4 days ago
Dr. Wayne Carson Koontz, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 129 Woodson St, Salisbury, NC 28144 Phone: 704-636-5576 Fax: 704-636-1755 | |
Dr. Mark David Lins, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 129 Woodson St, Salisbury, NC 28144 Phone: 704-636-5576 Fax: 704-636-1755 | |
Dr. Jennifer Garraty Hudson, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 129 Woodson St, Salisbury, NC 28144 Phone: 704-636-5576 Fax: 704-636-1755 | |
Dr. Kathleen F Russo, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 129 Woodson St, Salisbury, NC 28144 Phone: 704-636-5576 Fax: 704-636-1755 | |
Dr. Erron Joseph Towns, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 129 Woodson St, Salisbury, NC 28144 Phone: 704-636-5576 Fax: 704-636-1755 | |
Dr. Benjamin Herron Craighead, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 129 Woodson St, Salisbury, NC 28144 Phone: 704-636-5576 Fax: 704-636-1755 | |
Dr. Christopher John Magryta, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 129 Woodson St, Salisbury, NC 28144 Phone: 704-636-5576 Fax: 704-636-1755 |